Atika Capital Management’s NovoCure NVCR Stock Holding History

Atika Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-32,000	Closed	-$2.7M	–	99
2019 Q4	$2.7M	Sell	32,000 -5,690	-15%	-$459K	0.52%	60
2019 Q3	$2.82M	Buy	37,690 +4,700	+14%	+$376K	0.59%	54
2019 Q2	$2.09M	Sell	32,990 -25,010	-43%	-$1.27M	0.41%	69
2019 Q1	$2.79M	Sell	58,000 -2,500	-4%	-$120K	0.57%	60
2018 Q4	$2.03M	Sell	60,500 -136,500	-69%	-$4.99M	0.6%	59
2018 Q3	$10.3M	Buy	197,000 +107,000	+119%	+$4.26M	1.85%	15
2018 Q2	$2.82M	Buy	+90,000	New	+$2.5M	0.54%	69

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Atika Capital Management's NVCR Position: Q1 2020 in Review

Atika Capital Management sold out of NovoCure (NVCR) in Q1 2020, closing a stake of 32,000 shares — an estimated $2.7M sold.

Atika Capital Management first reported a position in NVCR in Q2 2018 and held it in 7 quarters. The position peaked at $10.3M in Q3 2018. 271 funds tracked by Wall St. Rank hold NVCR as of Q1 2020.

Atika Capital Management reported no remaining NovoCure position as of Q1 2020 after selling out during the quarter.
Atika Capital Management sold 32,000 NovoCure shares in Q1 2020, an estimated $2.7M.
Atika Capital Management first reported a position in NovoCure in Q2 2018 and held it in 7 quarters.
Atika Capital Management's NovoCure position peaked at $10.3M in Q3 2018.
271 funds tracked by Wall St. Rank held NovoCure as of Q1 2020.

Based on Atika Capital Management's 13F filing for Q1 2020, filed 14 May 2020.